N/A
Completed N=15,268
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
Hypertension · Metabolic Syndrome X
Source: ClinicalTrials.gov NCT00613314 ↗
Enrolled (actual)
15,268
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcomePrimary: Response Rate at the End of 30 Day Period — 41.4; 66.3; 31.2 Percentage of patients
Summary
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response Rate at the End of 30 Day Period |
41.4; 66.3; 31.2 | — |
| PRIMARY Response Rate at the End of 60 Day Period |
75.5; 88.1; 69.1 | — |
| PRIMARY Change in Systolic Blood Pressure (SBP) From Baseline |
30.2 | — |
| PRIMARY Change in Diastolic Blood Pressure (DBP) From Baseline |
15.9 | — |
| SECONDARY Percentage of Patients With Presence of Metabolic Risk Factor |
20.0 | — |
Eligibility Criteria
Inclusion Criteria
- Age > 45 years
- Increased waist circumference (>88.9cm [>35in] men, >78.7cm [>31in] for women)
- Elevated triglycerides (>150mg/dl)
- Low HDL cholesterol ( 130/>85mmHG)
- Impaired fasting glucose (>110mg/dl) (8)
- Hypertensive patient assessed to benefit from telmisartan based treatment
Exclusion Criteria
- Hypersensitivity to telmisartan, hydrochlorothiazide (HCTZ) and its excipients
- <3 months myocardial infarction (MI), stroke or severe heart failure
Data sourced from ClinicalTrials.gov (NCT00613314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.